Status:
COMPLETED
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd ...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes
- Patients who have been placed on dietary therapy/exercise therapy without achievement of glycemic control
- Outpatients
Exclusion
- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant cardiovascular disease
- Significant diabetic complications
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
236 Patients enrolled
Trial Details
Trial ID
NCT00351832
Start Date
June 1 2006
Last Update
May 9 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Tokyo, Japan